University of Arkansas Medical Sciences’ Investigator Receives $1.7m to Advance Myeloma Research
A researcher with the University of Arkansas for Medical Sciences (UAMS) received a National Cancer Institute grant for over $1.7 […]
University of Arkansas Researcher Awarded $3.14m for Myeloma Center Studies
A researcher from the University of Arkansas for Medical Sciences (UAMS) Myeloma Center received two grants totaling nearly $3.14 million […]
Israel Has Made Big Contributions Toward Finding Multiple Myeloma Cures
Although Israel is a small country of only 9.1 million it disproportionately contributes to research targeting treatments and hopefully someday […]
An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials
In this weeks podcast we talk to Patricia Carter a Hematology-Myeloma Research Nurse about patient engagement and retention in clinical […]
How Do We Measure Real-World Data Against Clinical Trials in Myeloma?
Although clinical trials are the driving force behind most oncology-related discoveries and FDA approvals, strict eligibility criteria restrict many patients […]
Myeloma UK and the UK Myeloma Research Alliance Launch New Research Program
Myeloma UK intensifies its initiatives as part of an ambitious program to make Myeloma history. This new collaborative model will […]
Otago University New Zealand Finds Roxithromycin can Treat Myeloma Cancer
TrialSite News includes excerpts from Business Herald. It reports a range of new roxithromycin research initiatives worldwide. For example, according […]
FDA Rejects Karyopharm Therapeutics Request for Accelerated Approval for Myeloma Treatment
OncLive reports that the FDA’s Oncologic Drugs Advisory Committee (ODAC) rejected Karyopharm Therapeutics’ request for accelerated approval of selinexor for […]
TrialWatch: Adding Daratumumab Extends PFS in Multiple Myeloma Patients
A phase 3 clinical trial recently revealed that when previously untreated multiple myeloma (MM) patients ineligible for transplant received a […]
ICAHN School of Medicine Investigator on Potential Biomarker for Novel Myeloma Drug
Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response […]
